Liu, A., Liao, H., Li, Z., Liu, J., Zhou, C., Guo, Z., Xie, H., Peng, C. (2016). New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 17(12), 5087-5094. doi: 10.22034/APJCP.2016.17.12.5087
Ai Ling Liu; Hong Qing Liao; Zhi Liang Li; Jun Liu; Cui Lan Zhou; Zi Fen Guo; Hong Yan Xie; Cui Ying Peng. "New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer". Asian Pacific Journal of Cancer Prevention, 17, 12, 2016, 5087-5094. doi: 10.22034/APJCP.2016.17.12.5087
Liu, A., Liao, H., Li, Z., Liu, J., Zhou, C., Guo, Z., Xie, H., Peng, C. (2016). 'New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer', Asian Pacific Journal of Cancer Prevention, 17(12), pp. 5087-5094. doi: 10.22034/APJCP.2016.17.12.5087
Liu, A., Liao, H., Li, Z., Liu, J., Zhou, C., Guo, Z., Xie, H., Peng, C. New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 2016; 17(12): 5087-5094. doi: 10.22034/APJCP.2016.17.12.5087
New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer
1Institude of Biology, School of Pharmaceutical and Biological Science, University of south China
2Reproductive Health Hospital of Nanhua-Xinghui in Hengyang City, Heng Yang 421001, Hunan Province, China.
3Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science, China.
4Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science,China
5Department of Anatomy, University of South China, Heng Yang 421001, Hunan Province, China
6Institute of Pharmacy and Pharmacology, University of South China, China
7Institute of Biological Science, The Key Laboratory of Biological Toxicology and Ecological Restoration of Hengyang City, School of Pharmaceutical and Biological Science, China
8Institute of Biology, School of Pharmaceutical and Biological Science, University of South China
Receive Date: 09 October 2016,
Revise Date: 14 December 2016,
Accept Date: 16 January 2017
Abstract
mTOR, the mammalian target of rapamycin, is a conserved serine/threonine kinase which belongs to the phosphatidyl-linositol kinase-related kinase (PIKK) family. It has two complexes called mTORC1 and mTORC2. It is well established that mTOR plays important roles in cell growth, proliferation and differentiation. Over-activation of the mTOR pathway is considered to have a relationship with the development of many types of diseases, including polycystic ovary syndrome (PCOS) and ovarian cancer (OC). mTOR pathway inhibitors, such as rapamycin and its derivatives, can directly or indirectly treat or relieve the symptoms of patients suffering from PCOS or OC. Moreover, mTOR inhibitors in combination with other chemical-molecular agents may have extraordinary efficacy. This paper will discuss links between mTOR signaling and PCOS and OC, and explore the mechanisms of mTOR inhibitors in treating these two diseases, with conclusions regarding the most effective therapeutic approaches.
Top